# CIML NK Cell in Head & Neck Cancer

> **NCT04290546** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 11 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Interleukin-15 Superagonist (N-803)
- **BIOLOGICAL:** CIML NK cell Infusion
- **DRUG:** Ipilimumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT04290546
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-12-16
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04290546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04290546, "CIML NK Cell in Head & Neck Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04290546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*